First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline ...

Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

Please provide your email address to receive an email when new articles are posted on . Seventy-three percent of patients treated with OTX-TKI were rescue-free up to 40 weeks. OTX-TKI led to an 89% ...

A real-world study demonstrated better survival outcomes when an immunotherapy is combined with a tyrosine kinase inhibitor rather than another immunotherapy therapy for intermediate-risk renal cell ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the ASRS meeting, ...

Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. Many patients with ...

Combining thoracic radiotherapy with first-line EGFR tyrosine kinase inhibitor (TKI) therapy improves progression-free survival by 6.5 months and overall survival by more than 8 months in patients ...